Assembly Biosciences (ASMB) Total Debt (2010 - 2011)

Assembly Biosciences' (ASMB) quarterly Total Debt came in at $1.3 million in Q2 2011, down 21.91% quarter-over-quarter from $1.7 million in Q4 2010.

Assembly Biosciences (ASMB) Total Debt (2010 - 2011) Analysis & Trends

Assembly Biosciences' Total Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.

  • On a quarterly basis, Total Debt changed N/A year-over-year to $1.3 million in Q2 2011; TTM through Jun 2011 was $1.3 million, a N/A change from a year earlier, with the FY2010 full-year figure at $1.7 million, changed N/A from the prior year.
  • Total Debt retreated to $1.3 million in Q2 2011 per ASMB's latest filing, from $1.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $1.7 million in Q4 2010 and bottomed at $1.3 million in Q2 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 959.06 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Assembly Biosciences 282.74 Mn 56.14 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2011 1.32 Mn
Dec 31, 2010 1.69 Mn